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A B S T R A C T
Background: Complete anatomical myocardial revascularization is associated with better angina 
control and lower rates of cardiac events. However, in a significant number of patients treated by 
percutaneous coronary intervention (PCI), complete revascularization is not achieved. Thus, the aim 
of this study was to evaluate factors associated with incomplete myocardial revascularization (IMR) 
in multivessel PCI patients.
Methods: This was a cohort study involving 1,049 prospectively and consecutively revascularized patients 
through PCI with treatment of two or more vessels, between 2012 and 2014, divided into two groups: IMR 
(n = 324; 30.9%) and complete myocardial revascularization (n = 725; 69.1%). 
Results: IMR was significantly associated with older age (66.5 years vs. 64.1 years; p = 0.003), arterial 
hypertension (92.2% vs. 86.0%; p = 0.006), chronic renal failure (36.4 % vs. 26.0%; p < 0.001), acute coronary 
syndrome (26.3% vs. 21.0%; p = 0.05), previous surgical revascularization (16.1% vs. 7.1 %; p = 0.001), 
saphenous venous graft lesions (3.4% vs. 1.0%, p < 0.001), and chronic occlusions (3.3% vs. 1.4%, p = 0.005), 
as well as lower access to drug-eluting stents (57.8% vs. 64.8%; p = 0.002). In-hospital clinical outcomes did 
not differ between the groups. 
Conclusions: IMR occurred in approximately one-third of treated cases, and a significant association was 
observed with a higher-risk clinical profile and with target lesion interventions commonly associated with 
lower procedure success. The degree of revascularization had no impact on in-hospital clinical outcomes.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Fatores predisponentes para revascularização angiográfica incompleta em 
pacientes com intervenção coronária percutânea de múltiplos vasos
R E S U M O
Introdução: A revascularização miocárdica anatômica completa está associada a um melhor controle dos 
sintomas anginosos e a menores índices de eventos cardíacos maiores tardios. No entanto, em substancial 
número de pacientes tratados por meio de intervenção coronária percutânea (ICP), não logramos sua 
obtenção. Assim, nosso objetivo foi avaliar os fatores associados à revascularização miocárdica incompleta 
(RMI) em casos de ICP multiarterial.
Métodos: Estudo de coorte envolvendo 1.049 pacientes revascularizados de forma prospectiva e consecutiva 
por meio de ICP com tratamento de dois ou mais vasos, entre 2012 e 2014, divididos em dois grupos: RMI 
(n = 324; 30,9%) e revascularização miocárdica completa (n = 725; 69,1%). 
Resultados: A RMI foi significativamente associada a faixa etária maior (66,5 anos vs. 64,1 anos; p = 0,003), 
hipertensão arterial (92,2% vs. 86,0%; p = 0,006), insuficiência renal crônica (36.4% vs. 26.0%; p < 0,001), 
síndrome coronariana aguda (26,3% vs. 21,0%; p = 0,05), revascularização cirúrgica prévia (16,1% vs. 7,1%; 
p = 0,001), lesões em enxertos venosos (3,4% vs. 1,0%; p < 0,001) e oclusões crônicas (3,3% vs. 1,4%; p = 
0,005), bem como a menor acesso a stents farmacológicos (57,8% vs. 64,8%; p = 0,002). Os resultados clínicos 
hospitalares não diferiram entre os grupos.
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Conclusões: A RMI ocorreu em cerca de um terço dos casos tratados, tendo sido observada associação 
significativa, com um perfil clínico de maior risco e com intervenções em lesões alvo comumente 
associadas com menor sucesso do procedimento. O grau de revascularização não gerou impacto nos 
resultados clínicos da fase hospitalar.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
When compared to surgical treatment, percutaneous coronary 
interventions (PCI) currently account for more than three-quarters 
of revascularization procedures performed in tertiary care hospi-
tals. However, one of the limitations of this procedure, obtaining 
complete myocardial revascularization (CMR), still occurs despite 
great advancements in the technique.1,2
CMR, whatever the type of revascularization used, has been wi-
dely preferred as it is associated with higher event-free survival and 
a better quality of life in treated patients, due to better control of the 
symptoms caused by coronary heart disease.1,3,4 Recently, a rando-
mized clinical trial that involved acute coronary syndrome (ACS) 
cases additionally suggested that even in this scenario, attaining a 
complete revascularization, treating non-culprit lesions early is 
more advantageous than incomplete myocardial revascularization 
(IMR), confirming the benefits of CMR.5 
However, for a number of reasons, a significant number of pa-
tients do not achieve complete revascularization, as a result of clini-
cal and angiographic factors, as well as variables related to the 
revascularization procedures themselves, resulting in IMR, which 
should be avoided whenever possible.1,3-7 
The aim of this research was to identify the different factors 
associated with IMR in a series of patients with multivessel coro-
nary heart disease submitted to PCI for the treatment of at least 
two vessels.
Methods
Between June 2012 and June 2014, 2,572 patients were conse-
cutively submitted to PCI at our institution, a large tertiary hospi-
tal, of which 1,049 (40.7%) had multivessel coronary artery 
disease and had two or more treated vessels. These cases were 
divided into IMR (n = 324; 30.9%) and CMR (n = 725; 69.1%) groups.
Patients were identified using a computer database and were 
prospectively included. The study was observational. There were 
no specific exclusion criteria, i.e., all cases that underwent multi-
vessel PCI with the minimum treatment of two vessels were in-
cluded in the analysis.  
Drug-eluting and bare-metal stents were used. PCI was perfor-
med using the conventional technique, with direct stent implan-
tation or pre-dilation left to the discretion of the interventional 
cardiologist responsible for its performance. Adjunctive pharma-
cology consisted of unfractionated heparin at a dose 70 to 100 IU/kg, 
administered immediately before the procedure, in order to 
achieve an activated clotting time ≥ 250 seconds; acetylsalicylic 
acid (loading dose of 200 mg and was maintenance dose of 100 mg 
daily) started at least 1 day before the intervention and was 
maintained indefinitely; and clopidogrel (loading dose of 300 or 
600 mg, and maintenance dose of 75 mg daily). In some ACS ca-
ses, prasugrel or ticagrelor was prescribed in usual doses. The 
dual antiplatelet regimen was maintained for 30 days in bare-me-
tal stent patients, and for 6 to 12 months in drug-eluting stent 
and/or ACS patients.
For PCI to be indicated, patients had to have symptomatic or in-
duced myocardial ischemia and at least one lesion with diameter 
stenosis ≥ 70% by the visual criteria in two or more target vessels. 
The treated vessels were differentiated into major epicardial vessels 
(left anterior descending, right coronary and left circumflex arte-
ries), secondary branches, or venous grafts. Left ventricular function 
was assessed by visual analysis in the right anterior oblique view, 
and moderate-to-severe impairment was considered  with 45% or 
lower ejection fraction.
The decision regarding the degree of revascularization to be 
achieved was established by individual analysis of clinical characte-
ristics, the results of functional tests, and the characteristics of tar-
get lesions observed at coronary angiography. In some selected 
patients, techniques such as intravascular ultrasound and fractional 
flow reserve were used as auxiliary methods in the therapeutic de-
cision-making process.
Procedures were considered successful when residual stenosis 
< 20% was obtained by the visual criteria in the absence of major 
complications (death, myocardial infarction, or urgent bypass sur-
gery). Acute myocardial infarction was characterized as the deve-
lopment of pathological Q-waves in at least two contiguous leads 
in the 12-lead electrocardiogram and/or an elevation in creatine 
kinase-MB fraction more than three-fold higher than normal le-
vels. CMR was defined as treatment of all coronary artery vessels 
(main or secondary) > 2.0 mm in diameter and ≥ 70% diameter ste-
nosis,6 and IMR was defined as the inability to treat all coronary 
vessels >70% diameter stenosis.
Statistical analysis 
Quantitative variables were described as absolute numbers and 
percentages, and compared with the Chi-Squared test. Qualitative 
variables were shown as mean and standard deviation, and compa-
red using the Student’s t-test. The software Statistical Package for 
Social Sciences (SPSS) version 17, Minitab version 16, and Excel 2010 
were used, considering significant values of p < 0.05. 
Results
Slightly over 40% of patients treated in the period met the study 
inclusion criteria and nearly one-third of them were of IMR.
Table 1 depicts the main baseline clinical characteristics, which 
showed clear differences between the groups, confirming the more 
complex clinical profile of the IMR group. There was a predomi-
nance of older age, previous surgical revascularization, and chronic 
renal dysfunction. The ACS clinical presentation also prevailed in 
the IMR group. 
Among the data associated with pre-procedure coronary angio-
graphy (Table 2), this study observed a higher percentage of lesions 
with severe calcification, interventions in venous grafts, and chronic 
occlusions in the IMR group; on the other hand, in the CMR group, 
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PCI predominated for the treatment of bifurcations and left anterior 
descending artery lesions. The other characteristics did not differ 
between the groups. 
Regarding the variables of the procedure, the highest percentages 
of drug-eluting stents use were recorded in the CMR group, and of ad 
hoc PCI, in the IMR group (Fig. 1). The other data showed no signifi-
cant differences between the groups, emphasizing that most PCI ad-
dressed two vessels (93.8% vs. 92.4%; p = 0.41); in the interventions, 
there was a predominance of stent implantation with a length of 18 
mm or longer (67.0% vs. 66.2%; p = 0.74). Almost 50% of the cases 
received stents < 3.0 mm (49.3% vs. 46.2%; p = 0.19).
Finally, Table 3 shows the main clinical outcomes of the in-hospi-
tal stay, which did not differ between the groups.
Discussion
Angiographic IMR is a common situation in routine cardiology 
practice, observed in slightly over 30% of the cases assessed in 
this study, lower than the almost 48% observed in the contempo-
rary SYNTAX study (PCI group), and close to the 37% noticed in the 
ACUITY (Acute Catheterization and Urgent Intervention Triage Stra-
tegY) trial, i.e., both in the elective and in the unplanned scena-
rios, the percentages of IMR are significant.3-7
This observation is clinically relevant, as IMR is accompanied 
by higher rates of symptom recurrence and major cardiac events 
in the late phase, including mortality.3-9 The results of a recent 
meta-analysis involving nearly 90,000 patients confirm this sta-
tement, as, in cases in which CMR was obtained, significant re-
ductions in mortality (29% reduction), myocardial infarction (22% 
reduction), and additional revascularizations (26% reduction) 
were observed, results that occurred regardless of the revascula-
rization method used (PCI or surgery) and the definition em-
ployed (angiographic or functional criteria). Other reports have 
shown the same trend in both elective situations or in the presen-
ce of ACS.4 Thus, it becomes evident that, when feasible, CMR is 
preferable and beneficial. However, as explained before, due to a 
series of clinical, functional, and angiographic factors, the ideal 
degree of revascularization is not effectively achieved in many 
situations, characterizing incomplete revascularization.3-7
In this study, carried out in the real-world scenario of PCI, which 
evaluated only cases submitted to multivessel intervention, characte-
ristics were identified that predisposed patients to IMR, as follows: 
older age, hypertension, chronic renal failure, prior coronary artery 
bypass surgery, ACS, saphenous venous grafts lesions or chronic oc-
clusions, PCI of vessels other than the left anterior descending artery 
or bifurcation lesions, non-availability of drug-eluting stents, and ad 
hoc interventions.
Table 1
Clinical characteristics.
Variables IMR 
(n = 324)
CMR 
(n = 725)
p-value
Age, years 66.5 ± 10.7 64.1 ± 10.1 0.003
Male gender, n (%) 230 (71.0) 506 (69.8) 0.70
History of smoking, n (%) 46 (14.2) 123 (17.0) 0.26
Diabetes mellitus, n (%) 128 (39.5) 261 (36.0) 0.28
Arterial hypertension, n (%) 299 (92.3) 624 (86.1) 0.006
Hypercholesterolemia, n (%) 254 (78.4) 523 (72.1) 0.04
Chronic renal failure, n (%) 118 (36.4) 189 (26.1) < 0.001
Previous myocardial infarction, n (%) 120 (37.0) 307 (42.3) 0.11
Previous CABG, n (%) 52 (16.0) 51 (7.0) 0.001
Previous percutaneous intervention, n (%) 41 (12.7) 123 (17.0) 0.09
Clinical presentation, n (%) 0.054
Stable angina 157 (48.5) 373 (51.4)
Silent ischemia 82 (25.3) 200 (27.6)
NSTE-ACS 59 (18.2) 123 (17.0)
STEMI 26 (8.0) 30 (4.1)
IMR: incomplete myocardial revascularization; CMR: complete myocardial revascularization; CABG: coronary artery bypass grafting; NSTE-ACS: non-ST-elevation acute coronary syndrome; STEMI: ST-seg-
ment elevation myocardial infarction.
Table 2
Characteristics of pre-procedure angiography.
Variables IMR 
(n = 324 patients, 667 vessels)
CMR 
(n = 725, patients, 1,492 vessels)
p-value
Treated vessels, n (%) < 0.001
LMCA 28 (4.2) 33 (2.2)
Left anterior descending artery 169 (25.3) 473 (31.7)
Right coronary artery 94 (14.1) 247 (16.6)
Left circumflex artery 130 (19.5) 274 (18.4)
Secondary branches 218 (32.7) 450 (30.2)
Venous grafts 28 (4.2) 15 (1.0)
Type of lesion B2/C, n (%) 314 (47.1) 709 (47.5) 0.77
Restenotic lesions, n (%) 22 (3.3) 69 (4.6) 0.23
Bifurcation lesions, n (%) 213 (31.9) 563 (37.7) 0.01
Chronic occlusions, n (%) 22 (3.3) 21 (1.4) 0.01
Severe calcification, n (%) 55 (8.2) 83 (5.6) 0.02
Three-vessel disease, n (%) 154 (47.5) 320 (44.1) 0.28
Moderate/severe LV dysfunction, n (%) 180 (55.6) 358 (49.4) 0.07
IMR: incomplete myocardial revascularization; CMR: complete myocardial revascularization; LMCA: left main coronary artery; LV: left ventricle.
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The subanalysis of the ACUITY trial, carried out in the setting of 
ACS, showed similar results, except for cases of PCI in patients with 
previous coronary artery bypass surgery and, consequently, in tar-
get lesions located in saphenous vein bypass grafts. Possibly, becau-
se it is a trial performed only in cases of ACS, patients with elevation 
in pre-procedure cardiac biomarkers and patients with noninvasive 
risk stratification were identified as high risk.6 
The SYNTAX study, in its subanalysis, found more discrepant re-
sults, as it mentioned dyslipidemias as the only clinical variable 
associated with IMR, together with angiographic characteristics 
such as chronic occlusions, severe tortuosity, presence of multiple 
stenoses in the same target vessel, and right coronary artery inter-
ventions. Because it is a comparative clinical trial with surgery, it 
also identified patients with higher surgical risk by the EuroSCORE 
as more likely to have IMR.7 
Thus, our results show similarities and differences in comparison 
with other recent contributions that analyzed the same theme.6,7 
Undoubtedly, the fact that the present study did not have exclusion 
criteria makes these cases much more comprehensive and represen-
tative of the real world with respect to patients included in rando-
mized studies, which always have strict inclusion/exclusion criteria, 
to a greater or lesser degree.6,7 
It is worthwhile to provide more details regarding these findings, 
as there appears to be coherent explanations for what was observed, 
in addition to the fact that clear interdependence between some of 
the factors was found.
Older patients tend to have more comorbidities, such as chronic 
renal failure and lower level of physical activity in their daily lives, 
as well as more vessels with more extensive calcification and a hi-
gher percentage of chronic occlusions.10,11 Furthermore, in very de-
bilitated patients and at the same time, very symptomatic ones, 
the isolated treatment of the stenosis apparently responsible for 
symptoms is usually chosen, aiming to improve quality of life over 
event-free survival. The latter situation is one of the few in which 
the choice of IMR is always preferred.10
Systemic arterial hypertension and chronic renal dysfunction 
coexist in many cases, as the first condition is a major predispo-
sing factor for the second.12,13 In patients with chronic renal 
failure, the cardiologist faces a dilemma: if CMR is indicated, 
there must be a greater exposure to renal function impairment, 
which may, in severe cases of contrast-induced nephropathy, re-
sult in temporary or permanent dialysis, morbidities that are 
potentially very detrimental to the quality of life and for survi-
val itself. Thus, in these situations, smaller branches or chroni-
cal ly occluded vessels are not commonly revascular ized, 
resulting in IMR.1,11 Additionally, especially in cases submitted to 
dialysis, there is a greater chance of angiographic/clinical reste-
nosis, which is also associated with a higher probability of in-
complete revascularization, especially if it is not possible to 
implant drug-eluting stents.11   
Individuals who were previously submitted to coronary artery 
bypass surgery tend to have more diffuse and complex coronary 
artery disease, both in the native vessels and in saphenous venous 
grafts. Chronic occlusions with unfavorable anatomy for PCI are 
commonly observed in these cases one of the most common cau-
ses of IMR. Moreover, many of target lesions located in saphenous 
venous grafts occur in very deteriorated vessels, preventing or 
Figure 1. Use of drug-eluting stents and ad hoc interventions. PCI: percutaneous coronary intervention; IMR: incomplete myocardial revascularization; CMR: complete myocar-
dial revascularization.
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Table 3
In-hospital clinical outcomes.
Variables IMR 
(n = 324)
CMR 
(n = 725)
p-value
Procedure success, n (%) 304 (93.8) 662 (91.3) 0.16
Major adverse cardiac events, n (%) 23 (7.1) 64 (8.8) 0.71
Death 3 (0.9) 3 (0.4) 0.31
Myocardial infarction 20 (6.2) 59 (8.1) 0.16
Emergency surgery 4 (1.2) 6 (0.8) 0.51
IMR: incomplete myocardial revascularization; CMR: complete myocardial revascularization.
Drug-eluting stents Ad hoc PCI
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hindering the performance of PCI, which often results in procedu-
ral failure.1,14 
PCI in ACS patients is also associated with IMR.1,5,6 In these cir-
cumstances, many interventionists choose to treat initially only 
the culprit lesion, identified by several details. Many of the inter-
ventions are carried out as ad hoc procedures, with revasculariza-
tion complementation depending on several factors, such as distal 
stenosis severity, symptom recurrence, and extension of the resi-
dual ischemia, which can be measured invasively or non-invasi-
vely.1, 5,6 T he pat ient 's  overa l l  condit ion and any present 
comorbidities also influence subsequent therapeutic decisions. 
Logistic details, such as the patient’s failure to return to undergo 
additional procedures, may also occur. Recently, the results of the 
PRAMI (Preventive Angioplasty in Acute Myocardial Infarction) 
study,5 which compared the isolated treatment of the culprit le-
sion with the preventive treatment of other significant large ves-
sels, provided new data to help therapeutic decision-making. 
During the 2-year follow-up, there were significant reductions in 
acute myocardial infarction (68% reduction) and refractory angi-
na (65% reduction), with a non-significant trend in mortality re-
duction (68% lower) in the preventive PCI group, confirming the 
clinical relevance of CMR, whenever feasible. 
Finally, the availability of drug-eluting stents also plays a sig-
nificant role in this context. These devices are definitively asso-
ciated with lower rates of angiographic/clinical restenosis, and 
their positive impact is even more pronounced in those more li-
kely to recur. Thus, in a situation of probable restenosis, such as a 
hypothetical case of a diabetic patient with a long lesion in a 
small-caliber vessel, the absence of these stents would almost 
certainly be accompanied by IMR. These statements can be de-
monstrated by the results of a large meta-analysis involving 
more than 270,000 patients published in 2009, in which the use 
of drug-eluting stents in a real-world scenario was accompanied 
by significant reductions in mortality, myocardial infarction, and 
additional revascularizations in late follow-up.14-16
Limitations
The following limitations should be mentioned: (1) as the au-
thors chose the angiographic criteria to define IMR, the obser-
ved results should not be extrapolated to situations that use 
other definitions, as differences could be observed in the same 
assessed population; (2) as the analysis included only cases of 
multivessel PCI, involving interventions in multiple vessels, the 
same care discriminated in the previous item should be taken 
into account for situations of IMR in cases undergoing PCI for the 
treatment of a single vessel – something common in clinical 
practice; (3) routine quantitative angiography was not perfor-
med in patients, i.e., the classification of the revascularization 
degree was based on the visual criteria for assessing target le-
sion severity, which is more inaccurate and may have influenced 
some of the observed results; (4) the sample size may have pre-
vented the identification of other factors that could be associa-
ted with IMR, such as diabetes, a condition that usually causes 
severe and diffuse coronary disease, common characteristics in 
IMR situations;17 (5) as not all causes of PCI failure were clearly 
depicted in the database, situations such as exaggerated tortuo-
sity and others, potentially able to predispose to IMR, could not 
be precisely assessed; (6) the lack of results of late clinical out-
come prevented the analysis of the clinical benefit, possibly very 
significant, of CMR compared to IMR.  
Conclusions 
This observational trial conducted at a tertiary center with a lar-
ge flow of patients, involving percutaneous coronary intervention 
for multivessel treatment in a real-world scenario, found that in-
complete myocardial revascularization occurred in approximately 
one of every three treated patients. The main factors significantly 
associated with this condition were higher-risk clinical profile and 
target-lesion interventions commonly associated with lower proce-
dure success (venous grafts and chronic occlusions), and lower avai-
lability of drug-eluting stents. Finally, it was observed that the 
degree of revascularization achieved did not have an impact on in-
-hospital outcomes. 
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